InvestorsHub Logo
Followers 29
Posts 2180
Boards Moderated 0
Alias Born 12/13/2016

Re: None

Monday, 03/11/2024 1:36:46 AM

Monday, March 11, 2024 1:36:46 AM

Post# of 460143
Lilly's Donanemab faces a more difficult and delayed approval process as the FDA looks at its efficacy and side effects such as brain swelling. That coupled with a slower market uptake of Biogen/Eisai's Leqembi gives 2-73 a bit more development time in the Alzheimer's market.

https://www.investors.com/news/technology/eli-lilly-stock-buy-now/?src=A00220
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News